Tango Therapeutics TNGX Stock
Tango Therapeutics Price Chart
Tango Therapeutics TNGX Financial and Trading Overview
| Tango Therapeutics stock price | 21.47 USD |
| Previous Close | 21.98 USD |
| Open | 21.76 USD |
| Bid | 16.82 USD x 200 |
| Ask | 27.55 USD x 200 |
| Day's Range | 21.36 - 23.49 USD |
| 52 Week Range | 2.12 - 28.41 USD |
| Volume | 3.05M USD |
| Avg. Volume | 3.36M USD |
| Market Cap | 3.34B USD |
| Beta (5Y Monthly) | 1.223 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.9 USD |
TNGX Valuation Measures
| Enterprise Value | 2.83B USD |
| Trailing P/E | N/A |
| Forward P/E | -14.528302 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 58.62873 |
| Price/Book (mrq) | 9.069494 |
| Enterprise Value/Revenue | 49.697 |
| Enterprise Value/EBITDA | -24.542 |
Trading Information
Tango Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.223 |
| 52-Week Change | 765.35% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 28.41 USD |
| 52 Week Low | 2.12 USD |
| 50-Day Moving Average | 22.26 USD |
| 200-Day Moving Average | 12.89 USD |
TNGX Share Statistics
| Avg. Volume (3 month) | 3.36M USD |
| Avg. Daily Volume (10-Days) | 3.05M USD |
| Shares Outstanding | 144.65M |
| Float | 69.6M |
| Short Ratio | 9.85 |
| % Held by Insiders | 1.38% |
| % Held by Institutions | 126.99% |
| Shares Short | 31.81M |
| Short % of Float | 22.28% |
| Short % of Shares Outstanding | 21.99% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -188.15% |
| Operating Margin (ttm) | -206.21% |
| Gross Margin | -126.79% |
| EBITDA Margin | -202.49% |
Management Effectiveness
| Return on Assets (ttm) | -20.68% |
| Return on Equity (ttm) | -38.41% |
Income Statement
| Revenue (ttm) | 56.99M USD |
| Revenue Per Share (ttm) | 0.46 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -72265000 USD |
| EBITDA | -115406000 USD |
| Net Income Avi to Common (ttm) | -107232000 USD |
| Diluted EPS (ttm) | -0.83 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 379.84M USD |
| Total Cash Per Share (mrq) | 2.63 USD |
| Total Debt (mrq) | 32.79M USD |
| Total Debt/Equity (mrq) | 8.38 USD |
| Current Ratio (mrq) | 27.378 |
| Book Value Per Share (mrq) | 2.547 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -141548992 USD |
| Levered Free Cash Flow (ttm) | -68235000 USD |
Profile of Tango Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 201 Brookline Avenue |
| ZIP | 02215 |
| Phone | 857 320 4900 |
| Website | https://www.tangotx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 137 |
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Q&A For Tango Therapeutics Stock
What is a current TNGX stock price?
Tango Therapeutics TNGX stock price today per share is 21.47 USD.
How to purchase Tango Therapeutics stock?
You can buy TNGX shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tango Therapeutics?
The stock symbol or ticker of Tango Therapeutics is TNGX.
Which industry does the Tango Therapeutics company belong to?
The Tango Therapeutics industry is Biotechnology.
How many shares does Tango Therapeutics have in circulation?
The max supply of Tango Therapeutics shares is 144.65M.
What is Tango Therapeutics Price to Earnings Ratio (PE Ratio)?
Tango Therapeutics PE Ratio is now.
What was Tango Therapeutics earnings per share over the trailing 12 months (TTM)?
Tango Therapeutics EPS is -0.83 USD over the trailing 12 months.
Which sector does the Tango Therapeutics company belong to?
The Tango Therapeutics sector is Healthcare.
Tango Therapeutics TNGX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}